Since the first description of FCE, FCE has been found to be associated with a number of conditions including central serious chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV), choroidal neovascularization (CNV), and age-related macular degeneration (AMD). [2] [3] [4] [5] [6] In particular, there appeared to be a higher prevalence of FCE in patients with CSC. [3] [4] [5] [6] [7] The aim of this study is to evaluate the prevalence, clinical features and outcome of FCE in patients presenting with CSC.
Material and methods
This was a retrospective study of consecutive cases with a clinical diagnosis of CSC confirmed by spectral domain OCT (SD-OCT) assessment in the Hong Kong Eye Hospital between January 2010 and December 2011. The study adhered to the Declaration of Helsinki and was approved by the local Ethics Committee. The medical notes of the patents were reviewed and clinical data such as visual acuity, ophthalmoscopic findings, SD-OCT, fundus autofluorescence (FAF) imaging, fluorescein angiography (FA), and indocyanine green angiography (ICGA) findings were recorded. SD-OCT, FA, and ICGA were performed using the Spectralis HRA-OCT system (Heidelberg Engineering, Heidelberg, Germany). Snellen visual acuity was converted to logarithm of the minimum angle of resolution (logMAR) units for statistical analysis. Statistical analysis was performed using a statistical software (StatPlus:Mac 2009, AnalystSoft Inc., Vancouver, BC, Canada). Demographic characteristics of the patients were summarized by descriptive statistics. Comparisons of continuous variables were performed using Mann-Whitney U-test or Wilcoxon sign-ranked test. A P-value of o0.05 was considered as statistically significant.
Results

Patients' characteristics
A total of 116 patients with a clinical diagnosis of CSC were included in the study. FCE was found in 11 eyes of 7 (6.0%) patients, including 5 males and 2 females. All patients were of Chinese ethnicity. The mean ± SD age of the CSC patients with FCE was 44.4 ± 5.9 years (range, 37-56 years), compared with 45.4 ± 9.6 years for CSC patients without FCE (range, 22-78 years; MannWhitney U-test, P = 0.69). The mean spherical equivalent refractive error of eyes with FCE was − 1.9 ± 2.2D (range, − 0.13D to − 5.5D), compared with the mean spherical equivalent refractive error of − 0.60D ± 1.7D (range, +2.0D to − 6.6D) for eyes without FCE (Mann-Whitney U-test, P = 0.063). The primary complaints of the CSC patients with FCE at presentation included blurring of vision (five patients), metamorphopsia (one patient), and scotoma (one patient). Three (42.8%) patients had a history of smoking and one patient had a history of intermittent oral corticosteroid use for asthma 3 years before presentation.
SD-OCT and angiography findings
Four (57.1%) patients were found to have FCE in both eyes on SD-OCT imaging. One of the seven patients had two excavations in one eye, while the remaining six patients only had one FCE lesion at the macula. The mean ± SD central subfield retinal thickness (CSRT) of eyes with FCE at initial presentation was 311.9 ± 88 μm (range, 155-454 μm). This compared with the mean ± SD CSRT of 377.5 ± 145 μm in patients without FCE (range, 179-974 μm). The mean CSRT of CSC eyes with FCE was significantly lower compared with those without FCE (Mann-Whitney U-test, P = 0.020). FAF was performed in five eyes and all showed mixture of increased and reduced autofluorescence at the site of FCE. Five eyes of five FCE patients had focal leakage on FA, four of which had ink-blot leakage appearance and one had smokestack leakage appearance. ICGA demonstrated localized hypofluorescent spot during both early and late phases in four FCE eyes, and diffuse hyperfluorescence in the late phase owing to choroidal hyperpermeability in seven FCE eyes.
Disease course of FCE eyes
The mean ± SD follow-up duration of the FCE patients was 16.5 ± 13.0 months (range, 1-30 months). At baseline, the mean ± SD logMAR visual acuity of the 11 eyes with FCE was 0.24 ± 0.34 (range, 0.00-0.5). Six eyes had nonconforming FCE and five eyes had conforming FCE at the initial presentation (Figure 1 ). Nine eyes with FCE were observed without any treatment. Six eyes had subretinal fluid and three eyes had serous pigment epithelial detachment at baseline. There was no serial change in the appearance of excavation except that one case developed increase in SRF after 2 months of followup ( Figure 2 ). Two eyes of nonconforming FCE with serous macular detachment due to subretinal fluid were treated with photodynamic therapy (PDT) using half-dose (3 mg/m 2 ) verteporfin (Visudyne, Novartis, Basel, Switzerland) and standard laser fluence (50 J/cm 2 ). In both cases, SRF resolved completely and there were improvements in visual acuity after treatment (Figure 3) . At the final follow-up visit, visual acuity of all 11 eyes with FCE remained stable with the mean ± SD logMAR visual acuity of 0.20 ± 0.29 (range, 0.0-0.4; Wilcoxon signranked test, P = 0.27).
Discussion
Several previous studies have reported a possible association between FCE and CSC. [3] [4] [5] [6] [7] In our study, the prevalence of FCE in CSC patients was found to be 6.0%, which was slightly lower compared with the prevalence of 7.8% reported by Ellabban et al 4 in 116 eyes with CSC. However, our rate was higher than the prevalence of 2.8% reported by Suzuki et al 6 in another Japanese study of 248 eyes with CSC. However, in contrast with previous studies, our study showed a much higher prevalence of bilateral FCE, in which four (57%) of the seven patients were found to have FCE in both eyes. This rate was higher compared with previous studies in which 0-24% of patients had FCE bilaterally. [3] [4] [5] [6] [7] [8] [9] The natural course of FCE remains unclear as most of the published studies were cross-sectional studies. There were only a few studies with longitudinal follow-up data available and the majority of the excavations appeared to remain stable with follow-up. 3, 4, 6, 10 In our study, two eyes with FCE and active CSC were treated with PDT using half-dose verteporfin and standard laser fluence. Both patients had visual improvement with complete resolution of subretinal fluid despite persistence of FCE after treatment.
With the use of OCT and ICGA, previous studies have reported thinning of the underlying choriocapillaris in CSC eyes with FCE. 4, 9, 10 This can be reflected by the presence of hypofluorescent spots that we observed in ICGA. Moreover, we also found that CSC eyes with FCE had significantly thinner CSRT compared with those without FCE. This might be owing to less severe leakage from the choroidal circulation in CSC eyes with FCE due to loss of choriocapillaris. Choroidal hyperpermeability is one of the main characteristic features of CSC and this can also be observed in the ICGA of all FCE eyes with CSC. Therefore, the choroidal hemodynamic disturbances in CSC eyes with FCE might involve a mixture of diffuse choroidal hyperpermeability with localized thinning of choriocapillaris.
In addition to CSC, FCE have also been shown to be associated with other retinal conditions including PCV, AMD, and idiopathic CNV. 5, [8] [9] [10] [11] [12] [13] Therefore, patients with FCE should be monitored regularly for the potential development of other retinal diseases. In particular, CNV complexes have been reported to develop within the boundary of the excavation. Most of these CNV were of classic leakage pattern on FA and these cases usually respond well to intravitreal antivascular endothelial growth factor therapy. 12, 13 There are several limitations associated with our study including the retrospective nature and the small number of cases. Nonetheless, we were able to follow-up these eyes and evaluated the FCE changes associated with CSC longitudinally. Our findings confirmed that FCE is not an Figure 1 Spectral domain optical coherence tomogrphay (SD-OCT) scans of the 11 eyes with focal choroidal excavation (FCE) at presentation. Six eyes had nonconforming FCE (a-e) and five eyes had conforming FCE (f-k).
uncommon feature in patients with CSC and it may be associated with choroidal hemodynamic disturbances. Moreover, FCE appeared to be more commonly seen in Asian populations as the previous reports were mostly from patients of Asian descents. Further prospective study with larger sample size will be useful to evaluate the natural history and the long-term treatment outcome of CSC eyes with FCE. 
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